The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck KGaA
Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Takeda Science Foundation
Research Funding - Bristol-Myers Squibb (Inst)
 
Xiuning Le
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; EMD Serono; Lilly; Spectrum Pharmaceuticals
Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst)
 
Remi Veillon
Consulting or Advisory Role - Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Roche
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Roche (Inst); Takeda (Inst)
 
Ian Churchill Anderson
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); EMD Serono (Inst); Hutchison MediPharma (Inst); Merck (Inst); Seagen (Inst); Turning Point Therapeutics (Inst)
 
Christine M. Bestvina
Consulting or Advisory Role - Abbvie; Abbvie (I); AstraZeneca; Creative Educational Concepts; Curio Science; Genentech; OncLive Clinical Congress Consultants; Pfizer; Seagen; Takeda
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - EMD Serono
 
Ingel Demedts
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Hengrui Therapeutics; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Masahiro Morise
Speakers' Bureau - AstraZeneca; Chugai/Roche; Lilly; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Egbert F. Smit
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
S. Peter Eggleton
Employment - Merck
Travel, Accommodations, Expenses - Merck
 
Aurora OBrate
Employment - Merck KGaA
 
Gordon Otto
Employment - Merck KGaA
Stock and Other Ownership Interests - Novartis
 
Rolf Bruns
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Karl-Maria Schumacher
No Relationships to Disclose
 
Paul K. Paik
Honoraria - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Calithera Biosciences; EMD Serono; GlaxoSmithKline; Takeda; Xencor
Consulting or Advisory Role - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Calithera Biosciences; EMD Serono; GlaxoSmithKline; Takeda; Xencor
Research Funding - Bicara Therapeutics; Boehringer Ingelheim; EMD Serono